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Abstract: Triazoles remain first-line agents for antifungal prophylaxis in high-risk haemato-oncology
patients, but their use is increasingly contraindicated due to drug–drug interactions and additive
toxicities with novel treatments. In this retrospective, single-centre, observational study, we present our
eight-year experience of antifungal prophylaxis using intermittent high-dose liposomal Amphotericin
B (L-AmB). All adults identified through our Antifungal Stewardship Programme as receiving L-AmB
prophylaxis at 7.5 mg/kg once-weekly between February 2012 and January 2020 were included.
Adverse reactions, including infusion reactions, electrolyte loss, and nephrotoxicity, were recorded.
‘Breakthrough’ invasive fungal infection (IFI) occurring within four weeks of L-AmB was classified
using European Organization for Research and Treatment of Cancer/Invasive Fungal Infections
Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study
Group (EORTC/MSG) criteria. Moreover, 114 courses of intermittent high-dose L-AmB prophylaxis
administered to 92 unique patients were analysed. Hypokalaemia was the most common grade
3–4 adverse event, with 26 (23%) courses. Grade 3 nephrotoxicity occurred in 8 (7%) and reversed in all
six patients surviving to 90 days. There were two (1.8%) episodes of breakthrough IFI, one ‘probable’
and one ‘possible’. In this study, the largest evaluation of intermittent high-dose L-AmB prophylaxis
conducted to date, toxicity was manageable and reversible and breakthrough IFI was rare. L-AmB
prophylaxis represents a viable alternative for patients with a contraindication to triazoles.
Keywords: hematopoietic stem-cell transplantation (HSCT); acute leukaemia; graft-versus-host
disease (GvHD); antifungal prophylaxis; amphotericin B; triazoles
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1. Introduction
Antifungal prophylaxis is recommended for selected patients undergoing cytotoxic chemotherapy
and hematopoietic stem-cell transplantation (HSCT) to reduce the risk of invasive fungal infection
(IFI) including candidiasis, aspergillosis and mucormycosis [1]. Because of their broad antifungal
spectrum, ease of administration, and ability to achieve target serum concentrations, mould-active
triazoles (e.g., itraconazole/posaconazole) remain first line agents in high-risk patients such as those
with acute myeloid leukaemia/myelodysplastic syndromes (AML/MDS) or undergoing treatment for
graft-versus-host disease (GvHD).
Triazole use is, however, often contraindicated due to their hepatic metabolism and toxicity as
well as QTc prolongation. Itraconazole and posaconazole are potent inhibitors of cytochrome P450
3A4 and p-glycoprotein, so numerous drug–drug interactions must also be considered [2]. Alongside
commonly used drugs a variety of interactions and additive toxicities exist between triazoles and both
established and novel treatments for hematological malignancy (Supplementary Table S1) [3–6].
Conventional Amphotericin B deoxycholate (C-AmB) is the most broad-spectrum antifungal agent,
with crucial activity against most Aspergillus spp., Candida spp., Mucor spp., and other environmental
moulds. Its unfavourable toxicity profile, notably electrolyte abnormalities, nephrotoxicity, and anaemia,
has hindered its use as a prophylactic agent [2,7,8]. AmBisome® (L-AmB) is a liposomal formulation
of Amphotericin B with a more favorable toxicity profile [9,10]. In an RCT of pyrexic neutropenic
adults, L-AmB was as effective as C-AmB, but associated with 2–6 times fewer drug-related side effects
and severe drug-related side effects were seen in only 1% vs. 12% (p < 0.01) [10].
To treat IFI, L-AmB is administered daily (dose 3–5 mg/kg/day) which, given its intravenous
route, is impractical for outpatients requiring antifungal prophylaxis. However, when administered at
higher doses (7.5–15 mg/kg), therapeutic levels of L-AmB persist in tissues for over a week without an
associated increase in toxicity, supporting intermittent high dosing [2,11–14]. Administering L-AmB
at 7.5 mg/kg (once-weekly) and 15 mg/kg (once only) to myeloma patients undergoing allograft
transplantation resulted in mean serum and buccal concentrations of the drug well in excess of Candida
and Aspergillus MICs after seven days [12] and doses up to 7.5–15mg/kg/day were well tolerated in
a maximally-tolerated dose pharmacokinetic (PK) study, although severe hypokalaemia was more
common in patients receiving >10 mg/kg/day (0% vs. 35%, p = 0.006) [15].
Since 1999, 15 studies have reported on the safety and efficacy of different regimens of intravenous
L-AmB prophylaxis in haemato-oncology patients: 12 were prospective and 5 RCTs, of which only one
(2017) trial had >100 patients per arm (Table 1) [9,11,12,14,16–27]. All eight cohorts using once-weekly
doses ≥7.5mg/kg have been small (<50 patients). In this single-centre, retrospective observational
study, we report our eight-year experience of the safety (toxicity/adverse events) and efficacy (incidence
of breakthrough IFI) of L-AmB prophylaxis in high risk haemato-oncology patients encompassing the
largest cohort of high-dose, intermittent L-AmB prophylaxis reported to date.
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2. Materials and Methods
St George’s hospital is a 1300-bed London tertiary referral centre treating patients with
haematological malignancy. It performs autologous and allogeneic HSCT; 29/year in 2009 rising
to an average of 50/year currently. Since October 2010, an Antifungal Stewardship (AFS) programme
has operated, incorporating weekly review of antifungal prescriptions for all adult inpatients and
Haematology Day Care Unit attendees.
Over the study period, our local antifungal policy recommended itraconazole and posaconazole
as 1st and 2nd line prophylactic agents for patients at high risk of IFI [1], who are routinely cared for in
positive-pressure HEPA-filtered single rooms. Where triazoles were contraindicated, not tolerated,
or deemed unsuitable, L-AmB was used as a 3rd line agent. Before February 2011, L-AmB was
administered at 1mg/kg/day. Between February 2011–February 2012, the policy changed to 3 mg/kg
× 3/week. In February 2012, following a positive report from another London institution [28] and
literature review of intermittent high-dose L-AmB prophylaxis, a regimen of 7.5 mg/kg once-weekly
was instituted and continues to the present day. Where antifungal prophylaxis relates to intensive
chemotherapy (or a novel agent), it is usually commenced at the time of, or prior to, the first dose.
Our local policy is that after a 1 mg test dose, L-AmB is infused over 2 h without routine
pre-medication in the first instance. In the event of a reaction, the infusion rate is slowed and
medications (e.g., chloramphenamine, paracetamol, and hydrocortisone) are administered at the
discretion of the treating physician for both the current and future infusions.
At-risk patients (e.g., all those receiving antifungal prophylaxis) undergo investigation
for IFI if there is persistent fever (>72 h) despite broad-spectrum antibiotics accompanied by
suggestive symptoms or signs. This investigation comprises blood cultures, a CT chest (plus CT
sinus/head/abdomen as indicated), serum galactomannan and serum beta-D-glucan. A bronchoalveolar
lavage (BAL, with prolonged fungal culture, galactomananan and Pneumocystis pneumonia polymerase
chain reaction testing) is pursued in response to CT chest findings. Whilst these investigations are
ongoing, prophylaxis is switched to empirical pre-emptive treatment with L-AmB (3 mg/kg/day)
if the patient is unwell. Voriconazole is initiated if investigations suggest invasive aspergillosis.
Asymptomatic patients are not routinely screened for IFI.
As part of ongoing clinical service evaluation, records of AFS reviews, including patient
demographics, antifungal drug/indication and recommendations made, were prospectively entered
into secure Microsoft Excel (v2003) and subsequently REDCap databases. We conducted a retrospective
evaluation of L-AmB prophylaxis in haemato-oncology patients, extracting data on any patient
receiving ‘L-AmB’ for the indication ‘prophylaxis’ between October 2010–January 2020 but only
patients receiving intermittent high-dose L-AmB (7.5 mg/kg once weekly) were included in the main
analysis. Patients without an underlying haematological condition, primarily under the care of another
medical institution or for whom the indication for L-AmB was treatment rather than prophylaxis,
were also excluded.
Information extracted included: underlying haematological condition (including HSCT); rationale
for antifungal prophylaxis; reason triazole contraindicated; L-AmB dosing/duration and reason for
ceasing L-AmB. Missing data were retrieved from paper and electronic medical records and pharmacy,
laboratory, and microbiology databases.
Adverse reactions to L-AmB were recorded including nephrotoxicity and hypokalaemia or
hypomagnesaemia related to L-AmB administration. Toxicity was graded as per the Common
Terminology Criteria for Adverse Events [29].
Episodes of ‘breakthrough’ IFI were classified as ‘proven’, ‘probable’ or ‘possible’ based on
EORTC/MSG criteria [30]. In line with a consensus statement [31] we took the date of breakthrough IFI
as the first radiological/clinical sign/mycological finding within the period of antifungal prophylaxis.
This in turn depends on antifungal drug half-life and dosing schedule: we defined L-AmB prophylaxis
course length as extending until the next dose would be due (i.e., one week with once-weekly
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prophylaxis) but included any IFI within 4 weeks of the last dose of L-AmB as a breakthrough, based on
the above PK data.
Data were analysed using Microsoft Excel v2019 and GraphPad Prism v8.4.2 (GraphPad software,
LLC, San Diego, CA, USA), using Fischer’s exact test for categorical variables and Mann-Whitney U
test for continuous variables.
After utilising the NHS Health Research Authority Decision Tools [32], no formal ethics approval
was considered necessary as persons accessing patient-identifiable data were members of the direct
care team doing so as part of a clinical service evaluation.
3. Results
During the nine-year period from October 2010 to January 2020, 147 L-AmB prophylaxis courses
were identified. Thirty-three were excluded: low-dose courses (daily 1 mg/kg/d or thrice weekly
3 mg/kg, n = 24), treatment not prophylaxis (n = 5); patient primarily under another institution
(n = 2); no underlying hematological condition (n = 2). The remaining 114 courses of intermittent
high-dose (7.5 mg/kg weekly) L-AmB prophylaxis administered to 92 unique patients were analysed
(all administered after February 2012). These courses amounted to 520 L-AmB infusions and 3640
patient-days of antifungal prophylaxis.
Baseline characteristics and rationale for L-AmB prophylaxis are shown in Table 2. Median (IQR)
patient age was 42 (29–57) years and 57% were male. The median course length was 24 (7–147)
days deriving from 3 (1–21) infusions. The most common indication for antifungal prophylaxis was
intensive chemotherapy/novel agent for induction/relapse (77%), the majority (78%) of whom had
acute leukaemia. Fourteen patients (12%) received antifungal prophylaxis in relation to HSCT and
ten (9%) due to GvHD. The most frequent contra-indications to a triazole were to avoid a drug–drug
interaction (51%) or abnormal liver-function tests (39%). Drug–drug interactions were usually related
to vincristine or myelotarg (88%).
Table 2. Baseline characteristics and rationale for intermittent high-dose L-AmB prophylaxis (n = 114).
Characteristic Frequency
Age, Median (IQR) 42 (29–57)
Male, n (%) 65 57%
Rationale for antifungal prophylaxis
Intensive chemotherapy/novel agent
(induction/relapse) a 88 77%
HSCT (All) 14 12%
Autograft (pre-engraftment) b 7 6%
Allograft (<100 days post-) c 7 6%
Immunosuppression for GvHD d 10 9%
Prolonged neutropenia (disease related) e 2 2%
Rationale for L-AmB (over triazole)
Triazole drug-drug interaction 58 51%
Vincristine 45 39%
Myelotarg 6 5%
Other f 7 6%
Abnormal liver function tests 44 39%
Unable to tolerate PO/absorption concerns 6 5%
Cardiomyopathy/risk of QTc prolongation 3 3%
Previous side effects/intolerance to triazole 3 3%
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Table 2. Cont.
Characteristic Frequency
Reason L-AmB prophylaxis discontinued
Triazole no longer contraindicated 69 61%
Antifungal prophylaxis no longer indicated 16 14%
Death/palliation 7 6%
Infusion reaction 7 6%
Nephrotoxicity 5 4%
Confirmed/suspected IFI 3 3%
Acute allergic reaction 5 4%
Other g 2 2%
a ALL 47, AML 22, NHL 7, HLH 6, MM 2, AA 2, MDS 2. b NHL 5, MM 2. c MDS 2, AA 2, AML 1, ALL 1, HL 1.
d ALL 4, AML 2, AA 1, MDS 1, MF 1, HL 1. e AML 1, AA 1. f Other triazole drug-drug interactions included:
Ritonavir (n = 1), Thiotepa (n = 2), Rifater/Rifanah (n = 2), Ethambutol n = 1), Imatinib (n = 1), Colchicine (n = 1).
g Other reason L-AmB discontinued: Transfer of care (n = 1), Noted to have reduced eGFR at baseline (n = 1).
AA, Aplastic anaemia. ALL, Acute lymphocytic leukaemia. AML, Acute myeloid leukaemia. GvHD, Graft vs.
Host Disease. HL, Hodgkin lymphoma. HLH, Hemophagocytic lymphohistiocytosis. HSCT, Hematopoietic stem
cell transplantation. IFI, Invasive fungal infection. L-AmB, Liposomal Amphotericin B. MDS, Myelodysplastic
syndrome. MM, Multiple myeloma. MF, Myelofibrosis. NHL, Non-Hodgkin lymphoma. PO, Per oral.
Of the 88 patients receiving antifungal prophylaxis in relation to intensive chemotherapy/novel
agent, 79 (90%) were severely neutropenic (<0.5 × 109/L) at some point during their L-AmB course.
Severe neutropenia lasted over 10 days in 56 (71%) of these courses and occurred for a median of three
days (IQR, 0–7) after L-AmB commenced.
Adverse events (AEs) and incidence of breakthrough IFI are summarised in Table 3. Nephrotoxicity
and electrolyte loss were the most frequent AEs. The most common grade 3–4 AE was hypokalaemia;
occurring in 26 (23%) of L-AmB courses. Hypomagnesemia was common (66%) but only one instance
was grade 3–4. Grade 3 nephrotoxicity was associated with eight (7%) L-AmB courses, with no
instances of grade 4 nephrotoxicity. Of these eight patients, seven had acute leukaemia and the
rationale for prophylaxis was either allograft (n = 3), intensive chemotherapy (n = 4) or GvHD (n = 1)
so all were likely to be receiving concomitant nephrotoxic medications. Excluding two patients who
died <30 days, creatinine returned to baseline in the remaining six by 90 days (3 within30 days) [33].
All infusion reactions were mild but 3 of 5 acute allergic reactions were grade 3–4. L-AmB prophylaxis
was discontinued due to toxicity in 17 (15%) of courses; infusion reaction (n = 7), acute allergic reaction
(n = 5) and nephrotoxicity (n = 5) (Table 2).
Table 3. Adverse events, breakthrough IFI and mortality (n = 114).
L-AmB Prophylaxis Duration
Course length, median days (range) 24 (7–147)
Number of infusions, median (range) 3 (1–21)
Adverse events a
Acute allergic reaction 5 4%
Grade 3 2 2%
Grade 4 1 1%
Infusion reaction 7 6%
Nephrotoxicity 65 57%
Grade 3 8 7%
Hypokalaemia 75 66%
Grade 3 22 19%
Grade 4 4 4%
Hypomagnesaemia 75 66%
Grade 3 1 1%
Breakthrough IFI 2 2%
Possible 1 1%
Proven/Probable 1 1%
90 day mortality 10 9%
With IFI (n = 2) 2 100%
Without IFI (n = 112) 8 7%
a Reported as any grade, followed by grade 3–4 reported separately if present. i.e., For ‘infusion reaction’ all
reactions were grade 1, 2. IFI, Invasive fungal infection. L-AmB, Liposomal Amphotericin B.
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In 114 courses of high dose intermittent L-AmB prophylaxis there were just 2 (1.8%) episodes of
breakthrough IFI. This incidence remained low (2.4%) even if only patients conventionally considered
high-risk are considered, e.g., intense chemotherapy for AML/MDS (n = 24), treatment for GvHD
(n = 10), and <100 days post allograft (n = 7). One patient undergoing intensive chemotherapy for
HLH developed ‘probable’ IFI 7 days into L-AmB prophylaxis [30]. Chest imaging revealed new
nodular perihilar air space opacities and Aspergillus fumigatus was isolated twice from sputum culture.
The second patient had a background of sibling allograft for ALL and developed ‘possible’ IFI two
weeks into L-AmB prophylaxis for immunosuppression related to GvHD. CT chest revealed bilateral
peribronchovascular consolidation with areas of discrete nodules and surrounding ground-glass
change supportive of fungal infection. Sputum culture and serum galactomannan were negative,
but serum beta-D-glucan was raised at 469 pg/mL. Both patients died within 90-days whereas the
90-day mortality for those without IFI was 8/112 (7%) (Table 3).
A sensitivity analysis was performed comparing intermittent high-dose L-AmB to the historic
cohort of 24 patients that received low-dose AmB prophylaxis between 2010–11. There were no
significant differences in nephrotoxicity (any grade, 57% vs. 42%, p = 0.18) (grade 3–4, 7% vs. 8%,
p = 0.69), hypokalaemia (any grade, 66% vs. 79%, p = 0.24) (grade 3–4, 23% vs. 37.5%, p = 0.1),
hypomagnesaemia (66% vs. 88%, p=0.05) or proven/probable IFI (1% vs. 4%, p = 0.3).
4. Discussion
Whilst novel targeted therapies represent an exciting development in the treatment of
haematological malignancy they present new challenges for antifungal prophylaxis [5]. Drugs such
as inotuzumab ozogamicin, ibrutinib, FLT3 inhibitors and venetoclax all have significant
interactions/additive toxicities with triazoles and some, such as ibrutinib, are associated with a
high incidence of IFI [34,35]. Safe, effective oral alternatives to azoles are urgently needed, with
several promising novel agents in clinical development [36–40]. In the meantime, intravenous agents
remain the most attractive option (although nebulised L-AmB may be an alternative [41]). Whilst
echinocandins are an option, they have a narrower spectrum than L-AmB, require daily intravenous
dosing, and are fungistatic (rather than -cidal) against Aspergillus spp. [2]. Our eight-year experience of
prophylactic L-AmB in high risk haemato-oncology patients includes the largest series of intermittent
high-dose courses to date, given for a median of 3–4 weeks. We found that these prophylactic regimens
were well tolerated with reversible toxicities and associated with a low (1.8%) rate of breakthrough IFI.
The pharmacokinetics of L-AmB support intermittent high-dose administration for several reasons.
Firstly, the efficacy of L-AmB is concentration-dependent so achievement of a high maximum drug
concentration in plasma (Cmax) compared to the fungal MIC—the Cmax/MIC ratio, is desirable [2,11,12].
Secondly, L-AmB (more so than C-AmB) accumulates in the reticulo-endothelial system and other
tissues for several weeks after administration, in a dose-dependent manner [13]. Lastly, L-AmB exhibits
non-linear pharmacokinetics meaning that it is preferentially cleared at higher doses [14].
These characteristics mean that when administered at higher doses, therapeutic levels of L-AmB
persist in tissues without an associated increase in toxicity. In one study, levels of L-AmB above the
MIC of most fungi were maintained for one week in mice lungs and six weeks in kidney/spleen after
administration of 15 mg/kg × 3/week for 2–5 weeks. Drug levels in kidney/spleen 3–6 weeks post
treatment were similar whether a daily (2.4 mg/kg × 5/week) or intermittent (15 mg/kg once-weekly)
dose was used [42]. In another study, a single high-dose of L-AmB protected immunosuppressed mice
against challenge with Histoplasma spp. seven days later and survival increased with higher dosing:
20% (5 mg/kg) to 60% (10mg/kg) and 80% (20 mg/kg) [43].
The largest clinical trial of standard-dose L-AmB prophylaxis to date has been the AmbiGuard
study (n = 355), a multi-centre randomized placebo-controlled trial of L-AmB prophylaxis (5 mg/kg
twice-weekly) in induction chemotherapy for ALL (Table 1) [21]. There were more serious AEs
considered related to the study drug with L-AmB compared to placebo (8% vs. 2%, p = 0.02) as well as
more hypokalaemia (any grade—35% vs. 18%, p < 0.001) and creatinine elevation (any grade—9% vs.
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0%, p < 0.001). Interestingly, however, patients receiving placebo were as likely to have their study
drug stopped due to an AE as those receiving L-AmB (22% vs. 27%, p = 0.37), suggesting that some of
the toxicity observed with L-AmB may be due to concurrent chemotherapy/HSCT conditioning.
In our study, as in others, the most common L-AmB toxicities were renal. Electrolyte loss and
nephrotoxicity occurred in 66% and 57% of patients respectively. Grade 3 nephrotoxicity occurred
in 7%, possibly exacerbated by concomitant use of other nephrotoxic agents, and was reversible in
all survivors by 90 days. Grade 3–4 hypokalaemia occurred in 23% of patients, a figure between
that of the placebo and L-AmB arms of AmbiGuard (18% and 35%, p < 0.001) (Table 3). Careful
monitoring and pre-emptive potassium and magnesium replacement can mitigate the risk of this
predictable AmB-related AE [44]. In patients with deranged liver function tests the risk of reversible
renal toxicity with L-AmB must be weighed against the risk of drug induced liver injury with
triazoles. Our policy is to continue with triazoles in patients with cholestatic liver enzyme derangement
(alkaline phosphatase and gamma glutamyltransferase) and modest elevations in transaminases
(alanine transaminase <150 IU/L), with exclusion of other causes and close laboratory monitoring for
worsening transaminitis
In a sensitivity analysis we found no suggestion of increased AEs associated with intermittent
high-dose L-AmB compared to the 24 patients that received lower doses, a finding echoed in other
studies. In a retrospective analysis of adults with newly diagnosed AML/high-risk MDS, drug-related
side effects were similar between patients receiving L-AmB prophylaxis 3 mg/kg × 3/week and 9 mg/kg
once-weekly (14% vs. 12%) [26]. In one study that employed L-AmB at 15 mg/kg, there were mild
infusion-related reactions in only six out of 53 (11%) of infusions and only one led to cessation [16].
The authors postulated their long infusion time of 6 h reduced AEs (our local policy is to administer
over 2 h).
Our 15% rate of discontinuation due to toxicity is lower than that seen in a prospective study
using the same L-AmB dose (33.3%) [24] and AmbiGuard (27%) [21]. This may reflect the patient
popuations involved or protocol-driven discontinuationin a clinical trial. In the PROPHYSOME
study [14] the trial group suspended enrolment into the SCT arm after AEs led to four of eight patients
discontinuing L-AmB (10 mg/kg once-weekly) after the first dose [14]. All patients received at least
one concomitant nephrotoxic medication and all eight SCT patients received cyclosporin. Interestingly,
L-AmB was better tolerated in patients receiving chemotherapy for acute leukaemia, which represents
most (76%) of our intermittent high-dose cohort. We too found suggestion that L-AmB toxicity
prompting discontinuation may be more common with HSCT than with intensive chemotherapy,
although the difference was not statistically significant, with four out of 14 (29%) vs. 12 out of 87
(14%) (p = 0.2). HSCT patients are frequently on concomitant nephrotoxic agents such as ciclosporin,
acyclovir and aminoglycosides.
In our cohort, only two (1.8%) of 114 L-AmB courses were associated with breakthrough IFI,
of which only one was proven/probable. This rate remained low (2.4%) when including only patients
conventionally considered high-risk for IFI. Studies on L-AmB prophylaxis report IFI occurring over
varying time periods ranging between only during prophylaxis to up to a year after the last dose
(Table 1). This may partly explain why our incidence of proven/probable IFI is lower than the 5–10%
reported [11,21,24] elsewhere.
Prospective comparative data on the efficacy of intermittent high-dose L-AmB prophylaxis are
scarce. In a prospective study by El-Cheikh et al., (2007) 21 adults receiving high-dose steroids for
GvHD post-allograft transplantation were administered L-AmB prophylaxis 7.5 mg/kg once-weekly.
Only one (5%) instance of proven/probable IFI was observed, two months after discontinuation of
L-AmB prophylaxis [24]. In a subsequent retrospective study, the rate of proven/probable IFD was
four out of 42 (10%) in the L-AmB group vs. 13 out of 83 (16%) in a comparator group of patients that
received ‘other antifungal prophylaxis’ (a triazole in 87%) [11].
In terms of regular standard-dose L-AmB prophylaxis, in AmbiGuard (5 mg/kg twice-weekly) [21],
there were fewer episodes of proven/probable IFI with L-AmB compared to placebo, but the difference
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was not statistically significant: 18 in 228 (7.9%) vs. 13 in 111 (11.7%) (p = 0.24), possibly due to study
underpowering. In a single-centre RCT by Mattiuzzi et al. [23] the incidence of IFI was the same (4%)
in both L-AmB (3 mg/kg × 3/week) and fluconazole+itraconazole arms. Finally, in a multi-centre RCT
from 1999 [9], there was no ‘proven’ IFI (broadly similar to EORTC/MSG’s ‘probable’ definition [30]) in
the L-AmB arm (2 mg/kg × 3/week) vs. three (3.4%) with placebo. This surprisingly low rate of IFI with
placebo may stem from the lack of diagnostics, including fungal biomarkers such as galactomannan,
available at the time.
Although clinical guidelines exist for diagnostic sampling in high-risk haematology patients,
IFI cases may have been missed in this retrospective evaluation. Under a prospective study protocol
more instances of clinical deterioration may have been classified as ‘possible’ IFI, and with increased
utilisation of bronchoscopy more diagnoses of ‘probable’ IFI might have been made. Inferring a
direct link between L-AmB and rates of breakthrough IFI, in particular comparisons between doses
and regimens, are limited by historic trends and the absence of a comparator group. Similarly, it is
difficult to ascertain whether toxicity observed was directly attributable to L-AmB given the intensive
chemotherapy/HSCT conditioning that our patients were also receiving. Moreover, some AEs not
recorded in patient notes (e.g., mild infusion reactions) may have been missed.
5. Conclusions
To conclude, with an ever-expanding list of triazole drug–drug interactions and additive toxicities
to consider, in our large single-centre experience, intermittent high-dose L-AmB prophylaxis represents
a safe and effective alternative in high risk haemato-oncology patients. To mitigate the inevitable but
reversible common renal toxicities of L-AmB, we recommend stringent monitoring and pre-emptive
hydration and electrolyte replacement, especially in the context of HSCT patients on concomitant
nephrotoxic agents. As the list of novel immunosuppressive agents associated with IFI risk expands,
prospective, adequately powered non-inferiority trials comparing L-AmB to triazoles and novel oral
antifungal prophylactic agents are needed to address the ever-present threat that IFIs pose to advances
in the treatment of haematological malignancy.
Supplementary Materials: The following are available online at http://www.mdpi.com/2309-608X/6/4/385/s1,
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